Eduardo Dunayevich
Overview
Explore the profile of Eduardo Dunayevich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1656
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia
Murthy V, Hanson E, DeMartinis N, Asgharnejad M, Dong C, Evans R, et al.
Schizophr Res
. 2024 Jun;
270:249-257.
PMID: 38943928
Deficits in N-methyl-d-aspartate receptor (NMDAR) signaling are implicated in the pathogenesis of schizophrenia. Luvadaxistat (TAK-831/NBI-1065844) is an investigational d-amino acid oxidase (DAAO) inhibitor that increases d-serine levels at NMDAR coagonist...
2.
Correll C, Citrome L, Singer C, Lindenmayer J, Zinger C, Liang G, et al.
J Clin Psychopharmacol
. 2024 May;
44(4):353-361.
PMID: 38767901
Purpose/background: Using data from KINECT® 4, a phase 3, 48-week study of valbenazine, post hoc analyses were conducted to assess long-term outcomes that are relevant to the real-world management of...
3.
ODonnell P, Dong C, Murthy V, Asgharnejad M, Du X, Summerfelt A, et al.
Neuropsychopharmacology
. 2023 Mar;
48(7):1052-1059.
PMID: 36928351
Several attempts have been made to enhance N-methyl-D-aspartate (NMDA) receptor function in schizophrenia, but they have yielded mixed results. Luvadaxistat, a D-amino acid oxidase (DAAO) inhibitor that increases the glutamate...
4.
Scheffer I, Halford J, Miller I, Nabbout R, Sanchez-Carpintero R, Shiloh-Malawsky Y, et al.
Epilepsia
. 2021 Aug;
62(10):2505-2517.
PMID: 34406656
Objective: Add-on cannabidiol (CBD) reduced seizures associated with Dravet syndrome (DS) in two randomized, double-blind, placebo-controlled trials: GWPCARE1 Part B (NCT02091375) and GWPCARE2 (NCT02224703). Patients who completed GWPCARE1 Part A...
5.
Patel A, Mazurkiewicz-Beldzinska M, Chin R, Gil-Nagel A, Gunning B, Halford J, et al.
Epilepsia
. 2021 Jul;
62(9):2228-2239.
PMID: 34287833
Objective: Lennox-Gastaut syndrome (LGS) is an epileptic encephalopathy that is often treatment resistant. Efficacy and safety of add-on cannabidiol (CBD) to treat seizures associated with LGS was demonstrated in two...
6.
Cohen J, Checketts D, Dunayevich E, Gunning B, Hyslop A, Madhavan D, et al.
Epilepsia
. 2021 Jul;
62(9):2218-2227.
PMID: 34265088
Objective: We conducted a post hoc analysis of two randomized controlled trials, GWPCARE1 (NCT02091375) and GWPCARE2 (NCT02224703), to estimate the time to onset of cannabidiol (CBD) treatment effects (seizure reduction...
7.
Gunning B, Mazurkiewicz-Beldzinska M, Chin R, Bhathal H, Nortvedt C, Dunayevich E, et al.
Acta Neurol Scand
. 2020 Sep;
143(2):154-163.
PMID: 32969022
Objectives: To assess the efficacy and safety profile of add-on cannabidiol (CBD) in patients with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) on clobazam and in the overall population of...
8.
Devinsky O, Thiele E, Wright S, Checketts D, Morrison G, Dunayevich E, et al.
Acta Neurol Scand
. 2020 Jun;
142(6):531-540.
PMID: 32592183
Objective: The efficacy of cannabidiol (CBD) with and without concomitant clobazam (CLB) was evaluated in stratified analyses of four large randomized controlled trials, two in Lennox-Gastaut syndrome, and two in...
9.
Miller I, Scheffer I, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry M, et al.
JAMA Neurol
. 2020 Mar;
77(5):613-621.
PMID: 32119035
Importance: Clinical evidence supports effectiveness of cannabidiol for treatment-resistant seizures in Dravet syndrome, but this trial is the first to evaluate the 10-mg/kg/d dose. Objective: To evaluate the efficacy and...
10.
Pi-Sunyer X, Apovian C, McElroy S, Dunayevich E, Acevedo L, Greenway F
Int J Obes (Lond)
. 2019 Jan;
43(10):2085-2094.
PMID: 30664661
Background/objectives: Prolonged-release (PR) naltrexone 32 mg/bupropion 360 mg (NB) is approved for chronic weight management as an adjunct to reduced-calorie diet and increased physical activity. Central nervous system-active medications have...